When Type 1 Diabetes and Seizures Occur Together: Understanding a Rare Autoimmune Connection

Type 1 diabetes is caused by the immune system mistakenly attacking insulin-producing cells in the pancreas. Autoimmune encephalitis is a separate condition in which the immune system attacks the brain, causing seizures and neurological symptoms. While these conditions are usually unrelated, researchers have identified a small group of patients who develop both—linked by the same autoantibody called GAD-65.

A systematic review of published medical literature identified 78 patients from around the world with this rare combination. The researchers analyzed their medical records to understand how often this overlap occurs, what symptoms patients experience, and what treatments helped.

One striking finding is that there is no predictable order to how these conditions appear. In 40% of patients, Type 1 diabetes was diagnosed first, followed later by seizures. In 29%, seizures or neurological symptoms came first, and Type 1 diabetes developed afterward. In 9%, both conditions emerged around the same time. The remaining 22% had unclear timelines in their medical records.

Patients ranged widely in age at first presentation, from 1 to 72 years old, with an average age of about 25 years. Nearly two-thirds of the patients in the review were female.

When doctors examined patients' brains using MRI scans, about three-quarters showed abnormalities. The most common finding was a pattern called temporal T2-FLAIR hyperintensity, which suggests inflammation in specific brain regions. Electrical recordings (EEG) of brain activity revealed abnormal patterns in the vast majority of patients tested.

Seizure control proved challenging for many. While nearly 60% of patients received standard antiseizure medications, 70% of those treated showed drug resistance—meaning their seizures continued despite medication. This difficulty controlling seizures underscores why additional treatment approaches were often needed.

Because standard seizure medications alone were often insufficient, about 73% of patients received immunotherapy—treatments designed to calm the overactive immune system. The most common approaches were intravenous immunoglobulins (antibodies given through an IV) and corticosteroids. These treatments aim to reduce the immune attack on both the pancreas and the brain.

Patients with this condition frequently had other autoimmune diseases as well. Four in ten had autoimmune thyroid disorders, and 17% had overlapping autoimmune neurological conditions. This pattern suggests these patients' immune systems may be prone to attacking multiple organs and tissues.

This research highlights an important point: when patients with Type 1 diabetes develop new neurological symptoms or seizures, doctors should consider the possibility of autoimmune brain inflammation. Testing for GAD-65 autoantibodies in both blood and cerebrospinal fluid may help identify this rare but significant overlap.

The outcomes varied among patients. Some experienced improved seizure control with treatment, while others continued to struggle. Some patients reported cognitive or psychological symptoms. Two patients in the review group died, though the causes were not detailed. These variable outcomes underscore the seriousness of this condition and the need for specialized, coordinated care.

Source: Autoimmunity reviews. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.